Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART Immunotherapy Targeting CD19 Negative Acute Lymphoblastic Leukemia
NCT04016129Phase 2Not yet recruiting
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jul 2027
- Primary completion
- Jun 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Shenzhen Geno-Immune Medical Institute. Planned start Jul 2027; status: not yet recruiting.
02
Drugs
4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT04016129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04016129.